Share Buyback Programme
10 September 2026
Genus plc
Share Buyback Programme
Genus (LSE: GNS; the “Group” or the “Company”), a global leader in animal genetics, announces that it is commencing a share buy-back programme (the “Programme”) pursuant to which it may repurchase up to £60 million of its ordinary shares (the “Shares”). The Programme is consistent with the Group’s capital allocation framework and reflects confidence in the Group’s financial position, long-term growth prospects and sustainable cash generation. The Programme will commence immediately and is expected to conclude during the second half of FY27.
The purpose of the Programme is to reduce the capital of an issuer. As such, Shares purchased by the Company will be cancelled.
The Programme will be carried out pursuant to a non-discretionary agreement with J.P. Morgan Securities plc (JPMS plc), under which the Company has established certain pre-set parameters in accordance with which purchases may be made during the Programme. JPMS plc shall purchase Shares as riskless principal (and not as agent of the Company). In accordance with the terms of the Programme, purchases of Shares may continue during closed periods of the Company. During any such period, JPMS plc will make its trading decisions in relation to the Shares independently of, and uninfluenced by, the Company, subject to the agreed parameters of the Programme and applicable law and regulation.
Any purchases of Shares by the Company will be carried out in accordance with (and subject to the limits prescribed by) the Company’s general authority to repurchase Shares granted by its shareholders from time to time, Chapter 9 of the Financial Conduct Authority’s UK Listing Rules and the Market Abuse Regulation (EU) No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended). The Programme will be discontinued in the event that the Company ceases to have the necessary general authority to repurchase Shares.
For further information please contact:
Genus plc Tel: +44 (0)125 634 5970
Jorgen Kokke, Chief Executive Officer
Andy Russell, Chief Financial Officer
Anand Date, Investor Relations & Sustainability Director
Tavistock Tel: +44 (0)207 920 3150
Nick Dibden; Katie Hopkins; Saskia Zilkha
About Genus
Genus is a world-leading animal genetics company. Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRRS1 Resistant Pig is a market leading innovation in gene editing which Genus is looking to commercialise in the porcine industry once further regulatory approvals are obtained.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Footnotes
1 PRRS (Porcine Reproductive and Respiratory Syndrome) Resistant Pig (“PRP”)
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE